HC Wainwright Reiterates “Buy” Rating for Femasys (NASDAQ:FEMY)

Femasys (NASDAQ:FEMY)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They presently have a $12.00 target price on the stock.

Separately, Chardan Capital dropped their target price on shares of Femasys from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th.

Femasys Stock Performance

Shares of NASDAQ:FEMY opened at $1.06 on Wednesday. The company has a market capitalization of $24.27 million, a price-to-earnings ratio of -1.31 and a beta of -2.83. The firm’s 50 day simple moving average is $1.14 and its 200 day simple moving average is $1.13. The company has a debt-to-equity ratio of 0.86, a current ratio of 3.94 and a quick ratio of 3.26. Femasys has a fifty-two week low of $0.73 and a fifty-two week high of $2.40.

Femasys (NASDAQ:FEMY) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). The firm had revenue of $0.55 million during the quarter, compared to analyst estimates of $0.40 million. Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%. As a group, sell-side analysts forecast that Femasys will post -0.84 earnings per share for the current year.

Institutional Trading of Femasys

Hedge funds have recently bought and sold shares of the stock. Aljian Capital Management LLC bought a new position in shares of Femasys during the 3rd quarter worth approximately $27,000. XTX Topco Ltd grew its stake in shares of Femasys by 123.9% during the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock worth $36,000 after acquiring an additional 18,004 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Femasys by 9.2% during the 3rd quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock worth $229,000 after acquiring an additional 17,473 shares in the last quarter. Finally, CM Management LLC grew its stake in shares of Femasys by 6.3% during the 2nd quarter. CM Management LLC now owns 425,000 shares of the company’s stock worth $484,000 after acquiring an additional 25,000 shares in the last quarter. 65.27% of the stock is currently owned by institutional investors and hedge funds.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.